1 / 1

Characteristics of Long Term Responders to Gemcitabine and Paclitxel

Characteristics of Long Term Responders to Gemcitabine and Paclitxel. Katz Daniela 1 , Elyan Firas 1 , Sonneblick Amir 1 , Merimsky Ofer 2 , Ospovat Inna 1 , Cohen Orit 1 , Salmon Asher 1 , Nechushtan Hovav 1 , Edelmann David 1 , Peretz Tamar 1 , Peylan-Ramu Nili 1

sierra
Download Presentation

Characteristics of Long Term Responders to Gemcitabine and Paclitxel

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Characteristics of Long Term Responders to Gemcitabine and Paclitxel • Katz Daniela1, Elyan Firas1, Sonneblick Amir1, Merimsky Ofer2, Ospovat Inna1, Cohen Orit1, Salmon Asher1, Nechushtan Hovav1, Edelmann David1, Peretz Tamar1, Peylan-Ramu Nili1 • Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel • Oncology Department, Sourasky Medical Center, Tel Aviv, Israel Background The combination of fixed-dose-rate gemcitabine and docetaxel has demonstrated efficacy in advanced uterine leiomyosarcoma and nonleiomyosarcoma sarcomas. We evaluated the tolerability and efficacy of modified taxol-gemcitabine (GemTax) protocol for patient with advanced sarcoma. The protocol was designed on a weekly basis to reduce toxicity. The purpose of this retrospective study was to evaluate the characteristics of long term-responders (≥12 treatments) to weekly GemTax, among pre-treated advanced high-grade sarcoma patients. Methods From May 2004 to October 2011, 48 advanced sarcoma patients were treated with combination paclitaxel (60-90 mg/m2) and gemcitabine (600-900 mg/m2 over 100 min), on days 1,8 of every 3-week cycle or on days 1, 8 and 15 of every 4-week cycle at a wide-range treatment lines. Two patients are still on the protocol. Results Fifteen patients (6 males and 9 females) completed 12 weekly treatments or more (mean 22.3 range 12-37) of which 4 completed >30 treatments. These include 5 leiomyosarcomas (one retroperitoneal), 2 uterine leiomyosarcomas, 3 MFH, 2 spindle sarcoma, 1 osteosarcoma, 1 adamantinoma and 1 pleomorphic rhabdomyosarcoma. GemTax was administered as 1st or 2nd line treatment in 2 and 8 patients, respectively, and as 3rd -6th line in 5. Of these patients, none achieved complete response (CR), 7/15 (47%) achieved a partial response (PR) and 8/15 (53%) had stable disease (SD). Median time to progression was 10.3 months (range 4-22 months) Median overall survival was 51.2 months (range 16-95 months). A lower starting dose of paclitaxel (60-70 mg/m2) and gemcitabine (600-700 mg/m2) characterized the 4 patients with responses >30 cycles. Only five patients required dose reduction ranging between 10-40% due to grade 3 hematological toxicity. None of these patients, however, had febrile neutropenia, or bleeding events, and all non-hematologic toxicities including neurotoxicity were manageable. Conclusions GemTax is a reasonable treatment option for patients with advanced pre-treated high-grade sarcomas. The regimen is well tolerated and dose adjustments do not seem to impact response.

More Related